Skip to content
aiqbench takeMachine Learning

aiqbench analysis

This study demonstrates how unconstrained machine learning models can invert causal medical relationships, such as associating higher cancer severity with lower risk, without triggering standard validation metrics like AUC or calibration. The authors introduce a counterfactual testing framework combined with monotonic constraints to correct these logical inversions while maintaining predictive performance. This work highlights the critical need for domain-informed constraints and specialized verification tools in clinical AI deployment to prevent dangerous prediction errors.
Sources coveringarXiv, LessWrong
What this isA model's reading of the article and related coverage, written for aiqbench. Not the publisher's words.

Fixing a Model That Learned Worse Cancer Means Lower Risk: Monotonic Constraints in Bladder Cancer Recurrence Prediction

arXiv3 min read

arXiv:2610.00858v1 Announce Type: new Abstract: Background and Objective: Clinicians expect recurrence risk to climb with cancer severity. In a UK multicentre trial, an unconstrained XGBoost model learnt that higher tumour stage and carcinoma in situ predicted lower recurrence risk, and discrimination, calibration, and SHAP were all blind to it. We developed a counterfactual testing framework to detect this inversion and a monotonic-constraint framework to remove it without hurting performance. Methods: BOXIT enrolled 472 patients with protocol-mandated cystoscopy across 51 UK sites (2007-2012); 435 had at least two years' follow-up (153 recurrences, 35.2%). We developed a counterfactual direction test and a monotonic-constraint correction, with constraint directions drawn from the EORTC and EAU risk systems, and evaluated both against unconstrained XGBoost and logistic regression on 18 predictors (seven directed) over 50 cross-validation folds. The test worsened each patient on one directed feature at a time to check whether risk fell; SHAP direction and calibration were also assessed. Key Findings and Limitations: Tumour stage and carcinoma in situ were associated with lower recurrence, opposite to medical intuition; the unconstrained model reversed carcinoma in situ counterfactuals in 90.2% of cases and stage in 74.3%. Discrimination ($\Delta$AUC 0.005, p=0.47), calibration, and SHAP magnitude were all blind to the inversion. Monotonic constraints eliminated every violation at no cost to discrimination (0.723 vs 0.718) and outperformed EORTC (p=8.9e-16). Limitations: single trial, internal-external validation only. Conclusions and Clinical Implications: A model that had learned this inversion passed every conventional check. A counterfactual direction test, run as a single refit with pre-specified monotonic constraints, catches this failure at no cost to performance and should be routine before clinical deployment.

Abstract:Background and Objective: Clinicians expect recurrence risk to climb with cancer severity. In a UK multicentre trial, an unconstrained XGBoost model learnt that higher tumour stage and carcinoma in situ predicted lower recurrence risk, and discrimination, calibration, and SHAP were all blind to it. We developed a counterfactual testing framework to detect this inversion and a monotonic-constraint framework to remove it without hurting performance. Methods: BOXIT enrolled 472 patients with protocol-mandated cystoscopy across 51 UK sites (2007-2012); 435 had at least two years' follow-up (153 recurrences, 35.2%). We developed a counterfactual direction test and a monotonic-constraint correction, with constraint directions drawn from the EORTC and EAU risk systems, and evaluated both against unconstrained XGBoost and logistic regression on 18 predictors (seven directed) over 50 cross-validation folds. The test worsened each patient on one directed feature at a time to check whether risk fell; SHAP direction and calibration were also assessed. Key Findings and Limitations: Tumour stage and carcinoma in situ were associated with lower recurrence, opposite to medical intuition; the unconstrained model reversed carcinoma in situ counterfactuals in 90.2% of cases and stage in 74.3%. Discrimination ($\Delta$AUC 0.005, p=0.47), calibration, and SHAP magnitude were all blind to the inversion. Monotonic constraints eliminated every violation at no cost to discrimination (0.723 vs 0.718) and outperformed EORTC (p=8.9e-16). Limitations: single trial, internal-external validation only. Conclusions and Clinical Implications: A model that had learned this inversion passed every conventional check. A counterfactual direction test, run as a single refit with pre-specified monotonic constraints, catches this failure at no cost to performance and should be routine before clinical deployment.

13 pages, 4 figures, 1 table. Supplementary material (15 pages) provided as ancillary files

Machine Learning (cs.LG)

arXiv:2610.00858 [cs.LG]

(or arXiv:2610.00858v1 [cs.LG] for this version)

https://doi.org/10.48550/arXiv.2610.00858 Focus to learn more arXiv-issued DOI via DataCite (pending registration)

XGBoost_references.bib

elsarticle-num.bst

figures/Fig02_stage-and-audit.pdf

figures/Fig_dose_response_horizon.pdf

figures/Fig_shap_discrimination.pdf

figures/Fig_site_dropout_vs_inversion.pdf

figures/Fig_stage_hr_three_ways.pdf

figures/Figure_reclassification_grid.pdf

figures/repeatedcv_DCA_cv.pdf

figures/repeatedcv_Figure_patient_gallery.png

figures/repeatedcv_shap_xgb_stability.pdf

supplementary_material.bbl

supplementary_material.tex

(9 additional files not shown) You must enabled JavaScript to view entire file list.

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.

Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.

Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.

Full text under the publisher's open licence · 400 words

Related coverage